Drug development company Enlivex Covid raises $ 46 million on the Nasdaq

Enlivex Therapeutics (NASDAQ: ENLV), the Israeli immunotherapy developer for the clinical phase, raised $ 46 million in a deal purchased. The company had planned to raise $ 10 million but the demand was so high that the amount had to be increased dramatically. HC Wainwright & Co. The role of the sole director to manage the book for display. Enlivex is working to develop drugs to treat cancer and sepsis, but they are positive results from its trial in the second phase of the Covid-19 Alloctera treatment on critically ill or critically ill patients with Covid-19, which caused its share price to rise and great interest in its latest offerings. Ichilov Hospital in Tel Aviv has reported success with the special Covid drug Enlivex reporting strong treatment results in the second phase of Covid. The trial included 16 patients without a control group, of whom nine were severely ill with Covid-19 and seven were in critical condition. Twenty-eight days after providing treatment for the first time to 16 patients, there were no deaths, and 14 of the 16 patients were discharged from hospital and returned home. Two of the patients are still in the hospital on ventilators in the intensive care unit. On average, patients were discharged from the hospital 5.3 days after starting treatment with Alloctera. The offering was priced at $ 20 per share for 2,296,107 shares, and the company’s share price is currently down 18.54% at $ 19.53, giving a market cap of $ 263.22 million, which is still 160% higher than its share price in beginning of the month. Enlivex also gave the insurer a 30-day option to purchase up to 344,416 additional ordinary shares at the IPO price. The company plans to conduct a larger trial of Alloctera on more seriously or critically ill Covid-19 patients. The President of Enlivex is Shai Novick and the CEO is Oren Hershkovitz. Posted by Globes, Israel business news – en.globes.co.il – February 10, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021